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Amniotic membrane (AM) is used to treat a range of ophthalmic indications but must be presented 
in a non-contaminated state. AM from elective caesarean sections contains natural microbial 
contamination, requiring removal during processing protocols. the aim of this study was to assess 
the ability of antibiotic decontamination of AM, during processing by innovative low-temperature 
vacuum-drying. Bioburden of caesarean section AM was assessed, and found to be present in low levels. 
Subsequently, the process for producing vacuum-dried AM (VDAM) was assessed for decontamination 
ability, by artificially loading with Staphylococcus epidermidis at different stages of processing. The 
protocol was highly efficient at removing bioburden introduced at any stage of processing, with 
antibiotic treatment and drying the most efficacious steps. The antibacterial activity of non-antibiotic 
treated AM compared to VDAM was evaluated using minimum inhibitory/biocidal concentrations (Mic/
MBC), and disc diffusion assays against Meticillin-resistant Staphylococcus aureus, Meticillin-resistant S. 
epidermidis, Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis. Antibacterial activity 
without antibiotic was low, confirmed by high MIC/MBC, and a no inhibition on agar lawns. However, 
VDAM with antibiotic demonstrated effective antibacterial capacity against all bacteria. Therefore, 
antibiotic decontamination is a reliable method for sterilisation of AM and the resultant antibiotic 
reservoir is effective against gram-positive and –negative bacteria.
Treatment of ocular surface disease, ulcers and infections remains a challenge. Severe bacterial ocular infections 
are commonly treated with corticosteroids and an intensive course of antibiotics1,2. However, the toxic side-effects 
of antibiotics can be harmful to epithelial cells of the cornea2,3.
Human amniotic membrane (AM), processed and preserved for therapeutic application is reported to pos-
sess anti-inflammatory, anti-scarring, anti-angiogenic and anti-microbial properties, which are valued for their 
role in wound healing and prevention of post-surgery complications4–7. Application of AM in the treatment of 
corneal disease has been reported to reduce infection-causing microorganisms and accelerate healing of infected 
corneas8, having been shown to be superior to antibiotic treatment alone7,9.
AM intervention is an option that mitigates the prolonged use of topical, broad-spectrum antibiotics, pre-
venting steroid-related complications. Studies supporting the use of AM for the treatment of corneal ulcers show 
significantly enhanced epithelial healing and a reduction in inflammation, corneal scarring, neovasculariza-
tion, and infection complications5,7,9. Although the mechanism of action of AM is not well explained, it is often 
attributed to bioactive substances such as growth factors, pro-inflammatory cytokines and anti-inflammatory 
cytokines, that enhance the function of structural constituents, working as a substrate for local cell migration and 
adhesion10.
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Freshly collected AM is rarely used for clinical treatment due to post-transplant complications11, increased 
probability of disease transmission, and short shelf-life. Therefore, most clinically used AM is subject to process-
ing and preservation steps prior to use10. Cryopreservation12, heat-drying13 and freeze-drying14 are the most com-
mon methods for AM preservation. Although associated with low post-transplantation infection complications15, 
cryopreservation has been shown to damage the amnion16 which impairs the viability and proliferative capacity 
of epithelial cells17, decrease levels of many bioactive substances including epidermal growth factors (EGF) and 
transforming growth factors (TGF), and is constrained by distribution difficulties18. Dried AM followed by radia-
tion sterilisation has been shown to be degraded with reduced growth factor content14. This effect on the stability 
and function of biological molecules such as growth factors, cytokines and structural proteins, affects the quality 
of the AM as a biological treatment for eye injury, and justifies the development of an appropriate approach for 
AM preservation.
Due to potential degradation by terminal sterilisation techniques19, AM is often aseptically prepared in order 
to ensure no contamination is introduced during processing and to limit the spread of any natural bioburden. 
In vivo during pregnancy, AM is considered sterile, however, potential microbial contamination originates from 
skin and vaginal flora during delivery of the placenta during birth, with the retrieving staff being an additional 
source of contamination20. Therefore, any manufacturing process must involve steps to effectively decontaminate 
such bioburden and allow for long-term preservation of AM.
Fresh AM processing generally involves a series of washing steps in physiological solutions to remove raw 
contamination and blood. Subsequent preservation via heat, freeze-drying, or deep freezing at below −60 °C are 
applied to suppress water activity to maintain tissue stability, and prevent microbial growth. However, to address 
bioburden contamination, antibiotics are typically added to the collection medium or storage medium for frozen 
AM20,21. For dried AM products, vacuum-packing followed by radiation sterilisation is often applied to ensure 
complete microbial inactivity22.
The sterility and integrity of final manufactured AM is necessary for safe and direct application. However, 
maintaining AM sterility, quality and functional properties during processing or storage is a challenge. 
Manufacturing AM in the presence of selected antibiotic/antifungal agents can have several advantageous fea-
tures, including avoiding deleterious effects on the matrix and biomolecules caused by terminal sterilisation, pro-
viding sterility, and inadvertently working as a potential antibiotic reservoir that offers a prophylactic treatment 
following transplantation.
The aim of this study was to validate the microbial decontamination potential of a novel vacuum-drying, asep-
tic manufacturing technique, and to then investigate further the lasting anti-microbial effects of antibiotics added 
during processing over long-term storage. We identify the level of microbiological contamination, or bioburden, 
of elective caesarean section (ECS) AM, and then go on to assess the robustness of decontamination during 
our optimised, innovative protocol for preserving AM, using vacuum-drying and a broad spectrum antibiotic/
antifungal cocktail18. This is done by artificially loading AM with high levels of Staphylococcus epidermidis, a skin 
floral species likely to contaminate amnion23, and investigating the decontamination efficacy of the washing, anti-
biotic treatment and vacuum-drying steps by counting the surviving colony forming units (CFU) using a spread 
plate method. The implications of biological and physical antimicrobial activity of fresh AM and the inadvertent 
antibiotic reservoir effect of vacuum-dried AM (VDAM) against strains of gram-positive and gram-negative 
bacteria are then studied using minimum inhibitory and biocidal concentrations (MIC/MBC) and disc-diffusion 
assays.
Results
natural bioburden of fresh ecS AM. Results demonstrating the normal (unloaded) floral contamination 
of fresh ECS AM can be seen in Table 1. Results showed that 40% of the fresh AM obtained from caesarean sec-
tion placentae were not contaminated with detectable bioburden. Of the remaining 60%, any contamination was 
predominantly identified as Neisseria cinerea or Micrococcus spp. Enhanced anaerobic incubation for seven days 
showed increased growth of Cutibacterium acnes bacteria in samples that were negative at aerobic conditions.
AM
Bacterial Identification
Blood Agar Culture Plates Basal Broth Culture
Aerobic (48 h) Anaerobic (7 days) Aerobic(48 h) Anaerobic (7 days)
1 Neisseria cinerea NG NG NG
2 Micrococcus spp. Cutibacterium acnes Micrococcus spp. P. acnes
3 NG 30 CFU/mL NG Cutibacterium acnes P. acnes Staph. schleiferi
4 NG NG NG NG
5 NG NG Micrococcus spp. NG
6 NG NG NG NG
7 NG NG Micrococcus spp. NG
8 NG NG NG Micrococcus spp.
9 NG NG NG NG
10 NG NG NG NG
Table 1. Bioburden assessment and identification of natural bioburden of 10 freshly collected ECS AM (NG – 
no growth).
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Validation of vacuum-drying protocol with artificially loaded bioburden. Due to low and incon-
sistent levels of natural bioburden on ECS AM, we artificially loaded 5 donated amnion with high bioburden (106 
CFU/mL), at different stages of processing, to effectively test the decontamination efficacy of the VDAM process. 
Figure 1, shows a schematic of the bacterial loading and sampling procedure performed. Unloaded samples of 
each donor (n = 3 per donor) were tested before washing in NaCl and no detectable contamination was seen.
Decontamination efficacy of full manufacturing run. The efficacy of the entire processing procedure 
to detach and devitalise bacterial contamination loaded at the start was examined by counting CFU/mL after 
each processing step (Fig. 2, graphs shown on log10 and linear scales). AM samples loaded with S. epidermidis 
showed significant successive reduction from the original load of 106 CFU/mL as processing progressed. Washing 
three times in NaCl reduced the bacterial load by almost one log cycle (post wash, 95.65%) and the removal of 
the spongy layer contributed to further lowering the remaining microbial load by 60.53%. Incubating the AM 
in raffinose solution containing a broad spectrum antibiotic cocktail (components listed in Table 2), caused the 
bioburden to be essentially eliminated, with no growth detected after raffinose/antibiotic incubation, or after the 
combined processing of raffinose/antibiotic incubation and vacuum drying (Fig. 2A,B). Incubating in raffinose 
without antibiotic (Fig. 2C,D) resulted in a further reduction of the remaining bacteria by 87.29% and continuing 
to the drying step without antibiotic treatment excluded more CFU by 94.26%.
Efficacy of raffinose/antibiotic incubation step. To test the efficacy of the raffinose incubation step 
with and without antibiotics, loading the AM was performed after the spongy layer removal step (Fig. 3A). This 
removes any effect that previous manufacturing steps had on the bacterial reduction. Incubation in raffinose con-
taining antibiotic effectively eliminated the loaded bacteria. Raffinose incubation without antibiotic removed the 
majority of loaded bacteria resulting in a 98.17% reduction, similar to that seen during the full run experiment.
Efficacy of vacuum-drying step. To test the efficacy of the vacuum-drying step, samples were loaded 
with S. epidermidis after the raffinose incubation and was performed with and without antibiotic (Fig. 3B). When 
antibiotic had been included in the process prior to loading, no CFU were found either in the loaded baseline or 
after drying (not shown on graph). When processed without antibiotics, the loaded baseline was lower than seen 
in previous experiments, indicating an inefficiency of loading at this point of processing. Subsequent drying then 
resulted in a 99.41% reduction of loaded bioburden.
Figure 1. Schematic diagram showing sampling procedures for the S. epidermidis loaded bioburden 
experiment. Discs of 25 mm diameter were collected at each point numbered in red (S1–S15). Experiment was 
performed on 5 separate donors.
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Antibacterial efficacy of AM. MIC/MBC test. MIC tests showed that washed AM extract without anti-
biotic treatment did not exert any consistent antimicrobial activity. Bacterial growth was observed across the 
96-well plates (Table 3); therefore, the MIC could not be determined. When the AM was incubated with antibi-
otic, the MIC results for each donor ranged from 0.78 µg/mL to 12.5 µg/mL, and the MBC results ranged from 
6.25 µg/mL to 25 µg/mL. These results indicate that the AM itself has very low natural antimicrobial properties but 
inclusion of the antibiotics in the process, even in small concentrations, can cause bacterial elimination.
Disc diffusion assay. Results from the disc diffusion assay can be seen in Fig. 4. The only samples to form a zone 
of inhibition (ZOI) against all 5 bacteria studied were VDAM and the positive control (AB). Effects from VDAM 
on MRSA (ZOI: 10.74 mm) and MRSE (ZOI: 15.87 mm) were higher than on those of E. coli (ZOI: 8.82 mm), P. 
aeruginosa (ZOI: 2.48 mm) and E. faecalis plates (ZOI: 1.96 mm). All samples of VDAM processed without anti-
biotic (R) VDAM, processed without raffinose or antibiotic (F), and the PVDF sample discs were not bactericidal 
to the five strains and did not produce ZOI. However, once the discs were removed there was reduced bacterial 
growth found below the sample (Fig. 4B). To test the number of bacteria that remained once the discs had been 
removed, swabs were taken and performed on a new plate (Fig. 4C), before visual assessment. VDAM and AB 
controls had eliminated all bacteria found directly below them. All other samples showed that viable bacteria 
remained below where the disc had been placed.
Figure 2. Effect of VDAM processing on reduction of artificially loaded S. epidermidis bacterial counts. 
Loading of 100 μL of 106 CFU/mL S. epidermidis was performed before washing procedures in 0.9% NaCl. AM 
samples were taken throughout processing and assessed for CFU/mL. Manufacturing was performed with 
antibiotic included in the raffinose step (A) graph shown with log10 scale, (B) graph shown with linear scale. 
Manufacturing with antibiotic included (C) graph shown with log10 scale, (D) graph shown with linear scale. 
Data shows individual experiments performed with 5 different donors and is represented as mean ± SEM. Data 
compared by one-way ANOVA, Kruskal-Wallis test followed by multiple comparison uncorrected Dunn’s test. 
Statistical significance vs. baseline represented by *p ≤ 0.05, ***p ≤ 0.001, ****p ≤ 0.0001.
Antibiotic Concentration % w/v Activity
Gentamicin 200 mg/mL 15–20 Gram-positive, gram-negative
Imipenem 10 mg/mL 5–10 Gram-positive, gram-negative
Polymyxin B 10 mg/mL 5–10 Gram-negative
Vancomycin 2.5 mg/mL <0.5 Gram-positive
Nystatin 125,000 U/mL <0.05 Antifungal
Table 2. Concentrations and activity of the antibiotic/antifungal cocktail used in this study.
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Diffusion assays performed over time (Fig. 5) showed that the antibacterial effects of the antibiotic release 
from VDAM could only be seen in full effect after certain time points. At 6 hours incubation, ZOI were meas-
ured from MRSA, E. coli and E. faecalis, but not from MRSE and P. aeruginosa. Notably, the antibiotic content of 
VDAM is released rapidly in the medium before the bacteria show a distinct growth in the first 6 hours.
Sterility test of VDAM held in long-term storage. VDAM samples that had been stored, vacuum-packed, at 
4–6 °C for over two years were placed into TSB or thioglycolate broth medium to test for contaminant growth. Of 
the 21 samples of 25 mm diameter that were tested, only one sample reported any growth, and only of aerobic bac-
teria. Two others from the same donor did not show any contamination. Of the 30 samples of 10 mm diameter, 1 
sample showed contaminant growth of both aerobic and anaerobic bacteria. Once again, two other samples from 
the same donor, processed identically, showed no growth. These samples were judged to have been contaminated 
during test handling.
Discussion
The natural floral contamination of fresh AM obtained by ECS in the Queens’s Medical Centre, Nottingham 
University Hospitals NHS trust, was shown to be considerably lower than literature reported from normal vag-
inal deliveries20,24,25. 40% of the tested AM showed no signs of bioburden contamination, similar to results pre-
viously reported (39%)20. Of those that demonstrated contamination, only Micrococcus spp, Propionibacterium 
acnes, S. schleiferi and N. cinerea were identified, most likely from skin contact of the placenta during delivery. 
Previous reports have identified up to 12 species in their surveys including the ones named in our study20,24,26. 
Staphylococcus spp have been identified as the most prevalent contamination of AM15,20,26. This study indicates 
that the risk of major contamination from AM obtained through ECS is low, reducing the risk of contaminated 
Figure 3. Efficiency of antibiotic incubation and drying steps in reducing artificially loaded S. epidermidis 
bacterial counts. (A) Loading of 100 μL of 106 S. epidermidis was performed before raffinose incubation with/
without antibiotic. AM samples were taken after loading and after incubation and assessed for CFU/mL. 
(B) Loading of 100 μL of 106 CFU/mL S. epidermidis was performed after raffinose incubation with/without 
antibiotic and before drying. AM samples were taken after loading and after drying and assessed for CFU/mL. 
Only samples processed without antibiotic are shown, as no colonies were seen either in the loaded baseline or 
after drying. Data represents experiments performed on 5 different donors and is represented as mean ± SEM. 
Data compared by one-way ANOVA, Kruskal-Wallis test followed by multiple comparison uncorrected Dunn’s 




Sample 1 Sample 2 Sample 3
MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL)
S. aureus 100 100 100 100 25 25
S. epidermidis 50 100 100 100 100 100
C. diphtheria 100 100 100 100 100 100
Moraxella 100 100 100 100 50 100
S. aureus 6.25 6.25 3.13 6.25 6.25 12.5
S. epidermidis 6.25 12.5 0.78 3.13 6.25 12.5
C. diphtheria 12.5 12.5 12.5 12.5 3.13 6.25
Moraxella 3.13 6.25 6.25 6.25 12.5 25
Table 3. MIC (Minimum Inhibitory Concentration) and MBC (Minimum Bactericidal Concentration) of 
serially diluted AM extracts treated with raffinose, with and without antibiotic treatment. Results are shown as 
average values from three separate experiments.
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AM being transplanted to the eye. Additional results from PBS samples collected immediately from raw AM 
before washing (incubated overnight at 35 °C on BA) contained no bioburden (n = 15 from 5 donors), demon-
strating that fresh AM could be bacteriostatic before processing.
VDAM was developed to be stored dry at room temperature in a stable state until use, avoiding the cold chain 
storage and distribution challenges associated with fresh and frozen AM. A bioburden-free VDAM final product 
was confirmed during investigation into our protocol, and long-term sterility test results confirm sterility of 
Figure 4. Antibacterial activity of various amniotic membrane preparations. Discs of 10 mm diameter were 
prepared of VDAM; non-raffinose and non-antibiotic treated AM (F), non-antibiotic treated AM (R) and 
antibiotic soaked Whatman no. 3 filter paper (AB) as a positive control. Polyvinylidene fluoride (PVDF) transfer 
membrane discs (PV) were used as a control to the following disc samples: F over PVDF (F/PV) and R over 
PVDF (R/PV). The transparent plastic material (P) was used as a carrier to transfer VDAM onto new for a 
further incubation period. All discs were laid on lawns of MRSA, MRSE, E. coli, P. aeruginosa and E. faecalis. 
Images show representative MHA plates after overnight incubation at 35 °C. (A) Bacterial lawns with discs still 
present. (B) Same plates after removal of samples. (C) Streaks from areas underneath discs, shown in B, onto 
lawns of corresponding bacteria on MHA plates after 35 °C overnight incubation. Experimental error caused 
MRSE sample P2 not to be streaked. Experiment conducted on three different donors.
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end-product samples, even when artificially high levels of S. epidermidis were loaded during different stages of 
processing. S. epidermidis is an ocular pathogen and was selected as a model of staphylococcus genera which is one 
of the most prevalent causes of bacterial keratitis27. It is considered to be one of the skin floral species most likely 
to contaminate AM, and has also been shown to adhere well to fresh AM23.
Our results revealed that three successive washes in 0.9% NaCl reduced bioburden by 95.65%, in agreement 
with Germain et al., (2010) who reported that frequent washing can reduce bioburden in processed heart valves28. 
Most AM preparation protocols use repeated washing in physiological saline to remove blood and immunogens, 
as well as remains of amniotic fluid. However, we have found that to retain the integrity of the epithelial surface 
and matrix biomolecules appropriate washing times have to be optimised18. As an added safety precaution for 
preserved AM, different antibiotic/antimycotic combinations can be used to cover a wide range of gram-positive, 
gram-negative bacteria and fungi, including penicillin, streptomycin, neomycin, amphotericin B, gentamycin, 
imipenem, nystatin, polymyxin and vancomycin29,30. We used a combination of the latter five agents, a cocktail 
widely used in the UK for tissue allograft banking31. Reports show that antibiotic solutions used for tissue allo-
graft preservation can be stored for up to one-year storage at −20 and −80 without effect on potency. Dried forms 
of these antibiotics can withstand storage at 37 °C for up to 12 months32.
Figure 5. Antibiotic release from VDAM over time. (A) Antibiotic release from 10 mm diameter discs of 
VDAM placed on bacterial lawns. Representative images show zones of inhibition of the same disc after 6, 12 
and 24 hours of incubation at 35 °C. Filter paper discs impregnated in antibiotic were used as control in every 
plate. Experiment performed on triplicate samples from 3 different donors and repeated 3 times for all bacteria. 
(B) Quantification of the zone of inhibition (including disc diameter) at the 6, 12 and 24 hour time points.
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The microbicide activity of antibiotic treatment was found to be more effective at 37 °C than at 4 °C or 22 °C28. 
Long antibiotic incubation, such as 12 hours at 37 °C, has been shown to be more efficient, but could potentially 
compromise the cell viability of tissue, including AM28,33,34. The current study showed that a two-hour incubation 
at 37 °C resulted in full eradication of bacteria loaded just before the antibiotic treatment step and that longer 
incubation times are not required. The antibiotic cocktail was capable of completely eradicating a high load of 
bacteria.
AM prepared in antibiotics can serve as a reservoir during transplantation, particularly effective against 
microbial keratitis frequently caused by different bacteria strains including the conjunctival normal flora S. epi-
dermidis27,35,36. AM can absorb and release antibiotics after rehydration on a wet surface such as agar medium or 
the corneal surface. Our results showed that the pattern of VDAM release of antibiotic was consistent with the 
antibiotic control discs, with rapid release at the beginning of application (6 hours) without considerable change 
in ZOI after 12 and 24 hours of incubation on bacterial lawns. AM has been shown to have slow antibiotic release 
over seven hours, dependent on the time of AM soaking in antibiotic37, however the release profile may be differ-
ent for different antibiotics38.
Dehydration of AM by air, heat or freeze-drying (lyophilisation) can be applied after washing procedures 
to decrease the water content of AM, hindering the spread of contamination during storage, and extending the 
shelf-life. Drying is applied as a final step before packaging, and has been found to maintain AM structural and 
biological molecules39. AM desiccated to lower or equal to 5% water content prevents microbial growth, thus 
there is less chance for product contamination. To confirm this, we showed that vacuum-drying alone, without 
antibiotic treatment, was efficient in removing 94.26% of bacteria, when samples were loaded after the raffinose 
washing step. Drying in our protocol is primarily applied to AM as a method of preservation and not as a decon-
tamination step, however, so as it was not efficient in reducing all of the bacterial load it would only ever be used 
as an adjunct to antibiotic treatment for decontamination.
Previous studies have shown that AM antibacterial function after washing or prolonged rehydration was sig-
nificantly reduced40. No ZOI was observed around washed AM against S. epidermidis38. Tehrani et al. (2013), 
showed a decrease in antibacterial activity against S. aureus, P. aeruginosa and E. coli of freeze dried AM after 
2 hours rehydration, and after 3 times rinsing in PBS41. Our MIC/MBC in vitro study of AM antibacterial activ-
ity showed that AM processed without antibiotics has little effect on S. aureus, S. epidermidis, C. diphtheria and 
Moraxella, indicating that AM has little intrinsic antimicrobial action without the inclusion of antibiotics during 
the manufacture process. To then investigate the role of the included antibiotics, we then decided to use bacterial 
strains that may show more resistance to the included antibiotic cocktail in disc diffusion assays. The results of 
these assays showed antibiotic processed VDAM has a variant ZOI on MRSA (10.74 mm) and MRSE (15.87 mm). 
Reduced activity was observed on E. coli (8.82 mm), P. aeruginosa (2.48 mm) and E. faecalis (1.96 mm) plates, but 
was still present and in a consistent manner. AM processed without antibiotic and/or raffinose were ineffective 
against MRSA, MRSE, E. coli, P. aeruginosa and E. faecalis strains with no ZOI, further indicating that washed 
AM untreated with antibiotic is not bactericidal.
Moreover, visual assessment of confluence of growth underlying the discs showed that bacteria did 
grow slightly underneath the control discs of plastic, PVDF and untreated AM, but not under VDAM and 
antibiotic-soaked filter paper. AM antibacterial action by adhesion was higher against gram-positive bacteria 
compared to gram-negative bacteria. This could be explained by the differences in defence mechanisms between 
both groups of bacteria42, and implies that fresh AM may have only a static antimicrobial action by adherence 
rather than a bactericidal effect, in agreement with Elian et al, 199140. Placing fresh AM on PVDF membrane, to 
evaluate the biological antibacterial activity by anti-microbial peptide stripping, demonstrated that samples of 
AM without antibiotics have no such effects against any tested bacteria. These findings disagree with that of N. 
Kjaergaard et al., 2001, who showed that saline washed AM placed over a nitrocellulose paper was inhibitive to 
underlying bacterial growth of group B streptococcus, Staphylococcus saprophyticus, P. aeruginosa and S. aureus43.
The current study was limited to investigating whether the antibacterial action of the dried amnion was due 
to the intrinsic properties of amniotic membrane or due to the antibiotics added during processing. This study 
could have been further extended by investigating the individual activity of the antibiotics within the cocktail 
and by considering the effect of long-term storage on each of the individual antibiotics. The study could also be 
extended by investigating the anti-fungal properties of both amniotic membrane and the antibiotic/antimycotic 
cocktail added during processing.
AM processed under approved guidelines and as a licensed protocol results in better wound healing results 
and less post-transplant infections15. This effect is most likely due to antibiotic use, providing an antibiotic res-
ervoir, substituting for the fresh AM’s lost antibacterial property and effective in prohibiting bacterial growth on 
wounds44. AM also functions as a physical barrier against infective pathogens40,45, with elastic, pliable properties 
allowing it to adhere completely to wounds23, preventing external infection recurrence.
The risk of major bioburden contamination of caesarean section collected AM is low. Nevertheless, the com-
bined AM processing procedure used in this paper is a robust method to remove any bioburden, sub-clinical 
infection, and manufacturing-related contamination. Non-antibiotic processed AM may be bacteriostatic but has 
no bactericidal effect. The specific VDAM processing steps of washing in NaCl, spongy layer removal, raffinose 
incubation and drying, all contribute to significantly reduce the bacterial load, with drying and antibiotic treat-
ment being considered a sterilisation step. The antibiotic reservoir of VDAM can eliminate natural and acquired 
contamination of gram-negative and gram-positive bacteria, such that VDAM is a reliably sterile product suitable 
for clinical application. Combined with vacuum packing, VDAM can be confidently and stably stored long-term 
without the risk of infection-related degradation.
9Scientific RepoRtS |         (2019) 9:12854  | https://doi.org/10.1038/s41598-019-49314-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Methods
Human amniotic membrane procurement and preparation. This study was carried out with the 
approval of the Nottingham Research Ethics Committee and the study (OY110101) complied with the tenets of 
the Declaration of Helsinki. Human placental samples were collected from consenting donors undergoing elective 
caesarean sections. Patients not complying with the inclusion criteria for tissue donation or having a history of 
antenatal problems were excluded. Written informed consent from the donor was obtained for sample use and the 
placenta membranes were prepared according to previously published methodology46.
Identification of the natural flora of amniotic membrane natural flora. AM samples (separated 
from the chorion membrane) from 10 different donors were studied for the natural bacterial flora contamination. 
Unwashed AM samples were collected in 5 mL PBS (Gibco®, ThermoFisherScientific, UK) before sonication for 
5 minutes. 200 µL of each sample was plated onto blood agar plates (Blood Agar Base No. 2 with sheep blood, 
Oxoid, UK) and incubated aerobically for 48 hours and anaerobically for 7 days at 37 °C, before colony forming 
units (CFU)/mL were counted. 100 µL volumes of sample were inoculated into Anaerobic Basal Broth (Oxoid), 
for 48 hours and 7 days at 37 °C in aerobic conditions to enhance bacterial proliferation. Bacterial growth was 
identified by turbidity and API® Staph Rapid 32 A microbial identification kit (BioMerieux, UK) was used to 
identify microorganisms.
Vacuum-dried amniotic membrane (VDAM) processing. AM was separated from the chorion mem-
brane by finger blunt dissection and triple washed in 250 mL 0.9% sodium chloride (NaCl) solution (Baxter, UK) 
for 15 minutes with rocking agitation to wash out blood. The spongy layer was removed by scalpel blade size 22 
attached to a custom-made tool. The AM were soaked in 100 mM raffinose pentahydrate (Acros Organics, UK) 
solution in DPBS containing 5 mL of a broad-spectrum antibiotic/antifungal combination (Source Bioscience, 
UK, see Table 2) and incubated at 37 °C for 2 hours. To prepare for vacuum-drying, the AM was spread out epi-
thelial side down over a sheet of parafilm and placed in a freeze dryer (Alpha 1–4 LSC, Advanced Freeze Dryer 
Christ® Osterode, Germany). Prior to sample drying the condenser was cooled to −45 °C to allow for vapour 
removal. Drying cycles consisted of a main dry phase of 30 minutes with a shelf temperature of 15 °C and vacuum 
pressure of 1.03 mbar followed by a final drying phase with a shelf temperature of 15 °C and vacuum pressure 
of 0.001 mbar for 15 minutes. After drying, AM was cut to the desired size and individually vacuum-packed in 
plastic pouches (Orved Multiple 315 Vacuum Sealer, Italy).
Validation of VDAM decontamination process. Bacterial culture. A pure culture of a clinical isolate of 
S. epidermidis was transferred from a BA plate into 20 mL universal tubes containing Tryptone Soya Broth (TSB) 
(Casein Soya Bean Digest Medium, CM 0129, Oxoid) and incubated overnight at 37 °C. The next day absorbance 
at 490 nm was measured using a Jenway 6705 UV/Vis Spectrophotometer (Fisher Scientific, Leicestershire, UK) 
and the bacterial suspension adjusted to 108 CFU/mL.
Bacterial loading of AM. Artificial loading of S. epidermidis was performed individually at three different 
stages of the VDAM process to assess the efficiency of the decontamination process at different steps (Fig. 1). 
To assess the entire process, the bacteria were loaded immediately after chorion removal and the samples taken 
and assessed for CFU at each stage. To assess the raffinose/antibiotic cocktail wash, the bacteria were loaded after 
spongy layer removal. To assess the drying stage bacteria were loaded after the incubation in raffinose (with/
without antibiotic) and before vacuum drying. Sampling of unloaded and loaded tissues was performed through-
out processing. Discs of 25 mm diameter were cut after collection of the AM. Bacteria inoculation was applied 
before each of the examined processing steps. To load the discs with S. epidermidis, a 2 mL microcentrifuge tube 
containing the AM sample in 1 mL PBS was inoculated with 100 µL of 108 CFU/mL S. epidermidis and agitated by 
rolling for 1 hour at 4 °C.
CFU counting. Loaded and fresh AM samples in 1 mL PBS were twice diluted to give 10−1 and 10−2 dilutions of 
each sample, then 200 µL of each dilution was spread onto each of three BA plates. The plates were incubated for 
48 hours aerobically (37 °C). The average of viable colonies was then counted and expressed as CFU/mL.
Minimum inhibitory concentration/minimum bactericidal concentration. Dry AM discs from 3 donors were pre-
pared with and without antibiotics. Proteins were then extracted from the tissue by grinding with pestle and mor-
tar in a liquid nitrogen bath. AM extracts were then tested against 106 CFU/mL of gram-positive; Staphylococcus 
aureus (S. aureus), S. epidermidis, Corynebacterium diphtheriae, and gram-negative Moraxella lacunata bacterial 
strains. 50 µL/well of lysogeny broth (LB) medium (Sigma-Aldrich) was added to appropriate wells of a 96-well 
plate, followed by 50 µL of AM extract at concentrations of 100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.20, and 
0.10 µg/mL loaded in triplicate across the plate. Culture medium only and medium with 100 mg/L gentamicin 
were used as negative and positive controls respectively. The bacterial strains were grown up in LB medium until 
optical density = 0.1 at 600 nm. 50 µL/well of the bacterial cell suspension added to each well of the plate. Plates 
were incubated overnight at 200 rpm on a rocker at 37 °C. Results were assessed visually with the minimum inhib-
itory concentration (MIC) equivalent to the last clear well, where bacterial growth is completely inhibited, and 
the minimum bacterial concentration (MBC) equivalent to the lowest concentration of test article required to kill 
99.9% of the initial bacterial inoculum.
Disc diffusion assay. The following AM samples were prepared for disc diffusion assays; VDAM processed 
with raffinose and antibiotic (VDAM), VDAM processed in raffinose without antibiotic (R) and VDAM with-
out raffinose or antibiotic (F). All samples were cut into discs of 10 mm diameter and kept in vials at 4 °C for a 
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maximum of 4 days before the experiment was performed. Cultures of multidrug resistant S. aureus (MRSA), 
multidrug resistant S. epidermidis (MRSE), Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa 
bacteria were prepared from fresh pure cultures in TSB. The viable bacterial count of each was adjusted to 108 
CFU/mL using 0.5 McFarland standard. Each of the five bacterial cultures were seeded onto three Mueller-Hinton 
agar (MHA) (Oxoid) plates in 90 mm Petri dishes using a sterile cotton swab and subsequently the AM discs 
were aseptically placed on the even lawns of the bacterial strains. An antibiotic-soaked disc of Whatman no.3 
filter paper (AB) was performed as a positive control and a disc of transparent laminating plastic (P) was used as 
a negative control. Three additional discs were also assessed, using hydrophobic highly stripping polyvinylidene 
fluoride (PVDF) transfer membrane discs, pore size 0.45 µm (Hybond™-P, Amersham Biosciences, UK), one of 
which was used alone as a control (PV). The PVDF was then used to separate the MHA surface and VDAM-R (R/
PV) and VDAM-F (F/PV) to assess biological antibacterial activity, rather than physical blocking. MHA plates 
were incubated at 35 °C for 18–24 hours and zone of inhibition (ZOI) were measured in mm using a digital calli-
per (Mitutoyo Absolute Digimatic Caliper, UK). To confirm whether there was any bacterial growth beneath the 
samples, sterile disposable loops were used to touch areas under the discs of the same bacterial plates and streak 
on another Tryptone Soya Agar (TSA, Casein soya bean digest agar, CM0131, Oxoid) plate before overnight 
incubation at 35 °C.
To specifically investigate time line of antibiotic release from VDAM samples, ZOI were measured at 0, 6, 12 
and 24 hours.
Sterility test of VDAM held in long-term storage. Triplicate samples of 25 mm diameter (average storage time 
757 days, 7 donors each with 3 samples) and 10 mm diameter (average storage time 862 days, 10 donors each 
with 3 samples) VDAM discs were tested for sterility. Discs were either aseptically immersed in falcon tubes con-
taining 40 mL TSB for aerobic bacteria, facultative bacteria and fungus, or placed in thioglycolate broth medium 
U.S.P. (CM0173, Oxoid) for anaerobic and facultative bacteria. TSB tubes were incubated at 35 °C with shaking 
(80 rpm), for 21 days along with negative and positive control tubes. Thioglycolate medium tubes were incubated 
for 21 days at 35 °C without shaking. Turbidity was used as an indicator of non-sterility and was checked daily. 
Streaking of 10 µL TSB from each tube was performed weekly on TSA plates, which were subsequently incubated 
for 5 days at 37 °C and observed for bacterial growth.
Statistical analysis. Statistical analysis was performed using GraphPad Prism version 7.01.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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